Table I.

Summary of major SCID mouse models and their properties

Mouse ModelGrafted HSCEngraftmentabMcBTThymusdReferences
bg/nu/xid-huBM or CD34+ BM<1%+(+)9 34
C.B-17 SCID-hu (Thy/Liv)107 FL<2% (0–15%)+(+)+5 6 56
hu-SRC C.B-17 SCID2–4 × 107 BM<1% (BM)+7
hu-SCR C.B-17 SCID15–50 × 106 UCB15% (BM)++8 12
NOD/SCID103–5 × 105 CD34+ UCB5% ± 11%++(+)(+)11 12 18 27 38 57
∼40 ± 40% (BM)<106
NOD/SCID∼105 CD34+ UCB29% ± 26%++++++18
NK depleted (TM-β1)79 ± 19% (BM)0.5–8 × 106
NOD/SCID/γc−/−0.4–2 × 105 CD34+ UCB∼45%++++19 58 59
35–75% (BM)2–5 × 105
Newborn105 CD34+ UCB∼70%++++42
NOD/SCID/γc−/−∼75% (BM)0.8–4.5 × 105
NOD/SCID/β2m−/−2 × 105 CD34+ UCB5–15% (BM)++??20 58
Newborn NOD/SCID/β2m−/−∼105 CD34+ UCB∼30% (BM)++(+)?42 43
C57BL/6 Rag2−/−γc−/−5 × 105 CD34+ UCB<1% (BM)++(+)?38
BALB/c Rag2−/−γc−/−∼105 CD34+ UCB (id. with FL)21 ± 16% (BM)++(+)(+)18 37 38 40
<106
Newborn BALB/c Rag2−/−γc−/−3.8–12.104 CD34+ UCB10–60% (BM)++++++39
20–65% (SPL)>106
Newborn BALB/c Rag2−/−γc−/−2–20 × 105 CD34+ FL>60% (PBL, LiV)++++++40
>50% (SPL, BM)2–10 × 106
  • a SPL, spleen.

  • b Percentage of huCD45+ cells in the PBL (or mentioned organs), 6–12 wk after transplantation.

  • c Presence of human hemopoietic-derived lineages: M, myeloid; B, B cells; and T, T cells.

  • d Engraftment of the murine thymus by human progenitors; when positive, absolute number of human (CD45+) thymocytes is mentioned.